Ftse Mib
39.712,66
0,45%
DAX
23.288,06
-0,45%
S&P 500
5.675,29
1,08%
NASDAQ
17.750,79
1,41%
Bitcoin
85.665,44
-1,41%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Rigel Pharmaceuticals Inc (RIGL) Rigel Pharmaceuticals Inc (RIGL) Notizie

Rigel Pharmaceuticals Inc

RIGL
20,44
0,11 (0,54%)
19 Mar 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/3/202501:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/3/202501:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/3/202501:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/3/202501:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/3/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/3/202522:41EDGAR2Form 3 - Initial statement of beneficial ownership of..
10/3/202522:22EDGAR2Form 8-K - Current report
10/3/202513:05PRNUSRigel Appoints Mark W. Frohlich, M.D. to Board of Directors
04/3/202522:14EDGAR2Form 8-K - Current report
04/3/202522:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
04/3/202522:01PRNUSRigel Reports Fourth Quarter and Full Year 2024 Financial..
25/2/202514:05PRNUSRigel Announces Conference Call and Webcast to Report Fourth..
14/2/202523:18EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
07/2/202502:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202502:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202502:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202502:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202521:58EDGAR2Form 144 - Report of proposed sale of securities
05/2/202521:43EDGAR2Form 144 - Report of proposed sale of securities
05/2/202521:41EDGAR2Form 144 - Report of proposed sale of securities
05/2/202521:40EDGAR2Form 144 - Report of proposed sale of securities
05/2/202519:23EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
04/2/202522:39EDGAR2Form 144 - Report of proposed sale of securities
04/2/202522:30EDGAR2Form 144 - Report of proposed sale of securities
04/2/202522:21EDGAR2Form 144 - Report of proposed sale of securities
04/2/202522:20EDGAR2Form 144 - Report of proposed sale of securities
01/2/202500:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202500:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202500:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202500:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202502:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202522:38EDGAR2Form 144 - Report of proposed sale of securities
22/1/202514:05PRNUSRigel's Fostamatinib Being Studied by National Institute of..
13/1/202514:15EDGAR2Form 8-K - Current report
13/1/202514:05PRNUSRigel Provides Business Update and 2025 Outlook
09/1/202514:05PRNUSRigel Announces R289 Granted Orphan Drug Designation by the..
08/1/202514:05PRNUSRigel to Present at the 43rd Annual J.P. Morgan Healthcare..
03/1/202514:05PRNUSRigel Pharmaceuticals, Inc. Announces Inducement Grants..
09/12/202422:15EDGAR2Form 8-K - Current report
09/12/202418:02PRNUSRigel Highlights Initial Data from Ongoing Phase 1b Study..
02/12/202414:05PRNUSRigel Announces R289 Granted Fast Track Designation by the..
27/11/202402:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202402:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202402:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202423:18EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202421:33EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202414:05PRNUSRigel to Present at the Jefferies London Healthcare..
07/11/202422:22EDGAR2Form 8-K - Current report
07/11/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202422:01PRNUSRigel Reports Third Quarter 2024 Financial Results and..
Apertura: 20,39 Min: 19,81 Max: 20,76
Chiusura: 20,33

La tua Cronologia

NASDAQ
RIGL
Rigel Pharmaceuticals
USOTC
GKSDF
Grupo Kuo SAB de CV (CE)
USOTC
TTHYF
Tethys Oil AB (PK)
USOTC
NWBTF
Newborn Town (PK)
USOTC
AMRPF
Amarin Printing and Publ... (CE)
USOTC
NZSTY
NZX (PK)
USOTC
NNWWF
North West (PK)
USOTC
NPSCY
Nippon Steel (PK)
USOTC
GFCOF
Good Flour (PK)
USOTC
AHLFS
RSE Archive (GM)
USOTC
GRTSQ
Gritstone bio (CE)
USOTC
TRNLY
Trendlines (QX)
USOTC
SIIXF
SIIX (PK)
USOTC
CGNMF
CGN Mining (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci